Moving Beyond the Basics: Implementation of a Radiopharmaceutical Therapy Program - RPT Workshop 2025

Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies. This onDemand workshop focuses on clinical indications, difficult cases, medical physics considerations, development of standard operating procedures for clinical implementation, billing, and safe theranostic delivery practices. Specifically, Radium-223, Lutetium-177 dotatate and Lutetium-177 PSMA-617 are discussed. The activity includes didactic presentation from physician experts from radiation oncology, nuclear medicine, medical oncology and medical physicists, with question and answer sessions to discuss practice implementation in various clinical settings (i.e., academic hospital vs. community practice, nuclear medicine vs. radiation oncology). The purpose of the activity is to increase physician, physicist and administration understanding on how to effectively and safely conduct a radiopharmaceutical program at their respective institutions. 

This activity is available from December 1, 2025, through 11:59 p.m. Eastern time on December 31, 2026.

This activity was originally presented and recorded at the 2025 ASTRO Annual Meeting. 

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, physicists, nurses, diagnostic radiologists, radiation therapists and radiation dosimetrists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the relevant principles of physics, pharmacology and radiobiology for radiopharmaceutical therapies (RPTs).
  • Identify clinical indications for RPTs that are currently approved for clinical use.
  • Identify logistical steps and common challenges in implementing RPT use in their own practice.
     
Course summary
Available credit: 
  • 4.50 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 4.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 4.50 Certificate of Attendance
    This activity was designated for 4.50 AMA PRA Category 1 Credit™.
Course opens: 
12/01/2025
Course expires: 
12/31/2025
Cost:
$379.00
Rating: 
0

The workshop onDemand includes the following presentations:

  1. Radiopharmaceutical Therapy Educational Resources and Radiobiology Update Update - Ana Kiess, MD, PhD
  2. Bench to Clinical Trials: Considerations for Theranostics Translation - Henry VanBrocklin, PhD
  3. Standard Operating Procedures for Radiopharmaceutical Therapies - Jacqueline Esthappan Zoberi, PhD, DABR, FAAPM
  4. Administrative and Billing Process of a Radiopharmaceutical Therapy (RPT) Program - Tina Visser, BS, CNMT
  5. Clinical Pearls from an Academic RO:NM Partnership - Hyun Kim, MD
  6. Panel Q&A Part 1 - Neil K. Taunk, MD, MSCTS - Moderator
  7. Integrating Lu177-PSMA with Other Systemic Options for Advanced Prostate Cancer - William K. Oh, MD
  8. Incorporating Theranostics into Prostate Cancer Clinical Practice - Bridget F. Koontz, MD, FASTRO
  9. Radioligand Therapy NET - Ravi Shridhar, MD, PhD
  10. Integrating Radiopharmaceutical Therapy and External Beam Radiation Treatment: Embracing the Exciting Semi-Unknown - Neil K. Taunk, MD, MSCTS
  11. New Isotopes and Indications in RPT - Michael R. Folkert, MD, PhD
  12. Panel Q&A Part 2 - Jacqueline Esthappan Zoberi, PhD, DABR, FAAPM - Moderator

Moderators:

  • Jacqueline Esthappan Zoberi, PhD, DABR, FAAPM, is employed by Washington University School of Medicine. Dr. Zoberi serves as a Board member at large with AAPM, session chair with ABS, and Chair of an ASTRO Safety white paper on radiopharmaceuticals. 
  • Bridget F. Koontz, MD, FASTRO is employed by Advent Health Cancer Institute, East Carolina University and Duke University. Dr. Koontz receives compensation/payment and has ownership equity in Rythera Therapeutics. Dr. Koontz serves as steering committee co-chair with IHE-RO, is associate editor of IJROBP, is a member of the NCTN GU Steering committee and is co-chair of the ancillary projects committee with NRG Oncology.
  • Neil K. Taunk, MD, MSCTS, is employed by Hospital of the University of Pennsylvania. Dr. Taunk receives compensation, honoraria and travel expenses from Boston Scientific, Point BioPharma, Novartis AG, Eli Lilly, GE Healthcare, Telix Pharmaceuticals and grant/research funding from Varian Medical Systems. Dr. Taunk serves as a committee member with the American Board of Radiology and is a member of the board of governors with CAMPEP.

Speakers:

  • Ana P. Kiess, MD, PhD, is employed by Johns Hopkins University School of Medicine. Dr. Kiess receives grant/research funding from Bayer, Novartis, Merck, Lantheus and Progenics Pharmaceuticals. 
  • Henry VanBrocklin, PhD, is employed by University of California, San Francisco. Dr. VanBrocklin receives grant/research funding from CellSight Technologies and serves as an advisor for Utter Therapeutics, ProLynx and Telix Pharmaceuticals. 
  • Tina Visser, CNMT, BS, is employed by Stanford Medicine. 
  • Hyun Kim, MD, is employed by Washington University School of Medicine. Dr. Kim receives grant/research funding and honoraria from Varian. Dr. Kim is the Founder and CEO of GlobalART. Dr. Kim serves as Associate Editor on the GI editorial board of IJROBP.  
  • William K. Oh, MD, is employed by Yale Cancer Center and Smilow Cancer Hospital. Dr. Oh receives honoraria as a consultant from Abbott, AstraZeneca, Biocartis, Cytogen, Neogenomics, Novartis, Pfizer, Sumitomo, VieCure and GSK. Dr. Oh serves as Chair of the National Prostate Cancer Roundtable with the American Cancer Society. 
  • Ravi Shridhar, MD, PhD, is employed by Advent Health Cancer Institute. Dr. Sridhar serves as an independent contractor with Boston Scientific (proctor), Astrazeneca (speaker) and Mirion Medical (consultant). 
  • Michael R. Folkert, MD, PhD, is employed by Fred Hutch Cancer Center, University of Washington Medical Center. Dr. Folkert serves as a radiation oncologist representative with the Advisory Committee on the Medical Uses of Isotopes and serves as Chair of the Education Subcommittee with American Brachytherapy Society. 

All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

Available Credit

  • 4.50 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 4.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 4.50 Certificate of Attendance
    This activity was designated for 4.50 AMA PRA Category 1 Credit™.

Price

Cost:
$379.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.

  • Nonmember: $379
  • Member: $249
  • Member-in-Training: $129
  • Student/Graduate Student/PGY-1 Member: $129
  • Postdoctoral Fellow Member: $129

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until December 31, 2026, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.